Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Injection · 1 trial · 4 indications
| Arm | Type | Description |
|---|---|---|
| Arm 1 | EXPERIMENTAL | C.001Low Dose |
| Arm 2 | EXPERIMENTAL | C.001 Medium Dose |
| Arm 3 | EXPERIMENTAL | C.001 High Dose |
| Name | Type | Description |
|---|---|---|
| Injection | BIOLOGICAL | C.001 administered once via subretinal injection |
Inclusion Criteria: * Age ≥18 years * Diagnosis of retinal disease associated with retinal pigment epithelium degeneration (e.g., geographic atrophy or Stargardt disease) * Visual acuity within protocol-defined limits * Stable ocular condition prior to enrollment * Medically suitable for ophthalmic...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Regeneron Pharmaceuticals, Inc. | REGN | 2 | PHASE3 | Pozelimab, Cemdisiran |
| Annexon, Inc. | ANNX | 1 | PHASE3 | Vonaprument |
| Belite Bio, Inc. ADR | BLTE | 1 | PHASE3 | Tinlarebant |
| Johnson & Johnson | JNJ | 1 | PHASE2 | JNJ-81201887 |
| AbbVie, Inc. | ABBV | 1 | PHASE1 | ABBV-6628, SYFOVRE |
| Sanofi SA Sponsored ADR | SNY | 1 | PHASE1 | SAR446597, Sham Comparator |
| Ocugen Inc | OCGN | 1 | PHASE1 | OCU410 |
| Apellis Pharmaceuticals, Inc. | APLS | 1 | - | Pegcetacoplan |
Single dose is an investigational drug being studied for the treatment of hypertension (HTN). It is currently in Phase 1 clinical development, with a completed trial evaluating its safety and tolerability in healthy adult subjects.
Single dose is being developed by cbdMD, Inc., a company traded on the stock exchange under the ticker symbol YCBD. The company is conducting clinical research on this investigational drug for hypertension.
Single dose is in Phase 1 clinical development. It is an investigational drug, not yet approved by regulatory authorities. One Phase 1 trial has been completed, and the drug remains under study for hypertension.
Single dose has one completed clinical trial, identified as NCT07529600, titled "A Phase I Clinical Study of ART101 Injection in Healthy Adult Subjects." This trial enrolled 40 participants in China and evaluated the drug in healthy volunteers.
Yes, single dose is also known as ART101. The completed Phase 1 clinical trial for this drug is titled "A Phase I Clinical Study of ART101 Injection in Healthy Adult Subjects," confirming that ART101 is the alternative name for single dose.